Cited by 221Nitric Oxide and Endothelin EffectsCardiovascular Health and Disease PreventionBiochemical effects in animals

The Pharmacodynamics of L-Arginine

Open access
Böger, Rainer H.·2007·The Journal of Nutrition

Abstract

L-arginine is a precursor for nitric oxide (NO) synthesis. NO is a ubiquitous mediator that is formed by a family of enzymes named NO synthases. In the brain, NO acts as a neurotransmitter; in the immune system, NO acts as a mediator of host defense; and in the cardiovascular system, NO mediates the protective effects of the intact endothelium, acting as a vasodilator and endogenous antiatherogenic molecule. About 5 g of L-arginine is ingested each day in a normal Western diet. L-arginine plasma levels are not significantly reduced in most disease conditions, except end-stage renal failure during hemodialysis treatment. Nonetheless, intravenous or dietary (oral) administration of relatively large doses of L-arginine has been shown to result in enhanced NO formation in subjects with impaired endothelial function at baseline. In several controlled clinical trials, long-term administration of L-arginine has been shown to improve the symptoms of cardiovascular disease. However, in other trials L-arginine was not beneficial, and in a recent study, the authors reported higher mortality of subjects receiving L-arginine than those receiving placebo. Recently it became clear that endogenous levels of asymmetric dimethylarginine (ADMA), a competitive inhibitor of L-arginine metabolism by NO synthase, may determine a subject's response to L-arginine supplementation. L-arginine appears to exert no effect in subjects with low ADMA levels, whereas in subjects with high ADMA levels, L-arginine restores the L-arginine/ADMA ratio to normal levels and thereby normalizes endothelial function. In conclusion, the effects of L-arginine supplementation on human physiology appear to be multicausal and dose-related. Doses of 3-8 g/d appear to be safe and not to cause acute pharmacologic effects in humans.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jn/137.6.1650s

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The ratio of l-arginine to ADMA appears to be a better indicator of cardiovascular risk.

    “As pointed out above, the ratio of l-arginine to ADMA appears to be a better indicator of cardiovascular risk (28, 103, 104, 606, 1050).”
  • When ADMA levels are low, effects of exogenous l-arginine are limited; therapy seems more beneficial in patients with higher ADMA levels, in which treatment increases l-arginine/ADMA ratios and improves endothelial function.

    “It has been noted that when ADMA levels are low, the effects of exogenous l-arginine are limited; however, the therapy seems to be more beneficial in patients with higher ADMA levels, in which the treatment increases the l-arginine/ADMA ratios and improves endothelial function (103).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 4

  1. Souci SW, Fachmann W, Kraut H. The composition of nutrients, nutrient tables, 5 th edition. Medpharm Scientific Publishers, Stuttgart; 1994.
  2. Bode-Bo ¨ger SM, Bo ¨ger RH, Galland A, Junker W, Tsikas D, Fro ¨lich JC. Pharmacokinetic-pharmacodynamic relationship of the effects of intra- venous and oral L-arginine on nitric oxide formation and peripheral haemodynamics in healthy human subjects. Br J Clin Pharmacol. 1998; 46:489-97.
  3. Giugliano D, Marfella R, Verazzo G, Acampora R, Coppola L, Cozzolinop D, D'Onofrio F. The vascular effects of L-arginine in humans. J Clin Invest. 1997;99:433-8.
  4. Schwedhelm E, Tan-Andresen J, Maas R, Riederer U, Schulze F, Bo ¨ger RH. LC-tandem MS method for the analysis of asymmetric dimethyl- arginine (ADMA) in human plasma. Clin Chem. 2005;51:1268-71.

Cited by

Sorted by citations

Authors
Böger, R. H.
Affiliations
University Medical Center Hamburg-Eppendorf (DE)
Corresponding author
Böger, Rainer H.
Venue
The Journal of Nutrition
Publisher
Elsevier BV
Published
2007-06
Volume
137
Issue
6
Pages
1650S-1655S
ISSN
0022-3166 (ISSN-L)
OpenAlex
W2115875498
Cited by
221
References
61
Citations by year
2026: 14 · 2025: 9 · 2024: 11 · 2023: 12 · 2022: 10 · 2021: 10 · 2020: 14 · 2019: 12 · 2018: 14 · 2017: 11 · 2016: 16 · 2015: 11 · 2014: 12 · 2013: 13 · 2012: 12
FWCI
1.04
Type
journal article
Language
en
Open access
Locations
  • Journal of Nutrition (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Deutsche Forschungsgemeinschaft
  • Deutsche Herzstiftung
Topics
  • Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
  • Health Sciences › Medicine › Physiology › Biochemical effects in animals
Keywords
L-arginine, nitric oxide, nitric oxide synthase, asymmetric dimethylarginine, endothelial function, cardiovascular disease, dietary supplementation, pharmacodynamics, dose-response relationship, end-stage renal disease, vasodilation, antiatherogenic effects
MeSH terms
Arginine, Cardiovascular Diseases, Humans, Nitric Oxide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review